A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients - possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Anemia is a major problem in patients…